Dr. Lambert is a regular researcher at the CHU de Québec-Université Laval Research Center and an assistant professor at the Faculty of Medicine of l’Université Laval in the department of Molecular Medicine. Dr. Lambert’s work aims to decipher how epigenetic regulators are assembled into functional units at the level of chromatin and how they impact transcription in healthy and cancerous cells. To address these fundamental questions, Dr. Lambert employs a multidisciplinary approach that includes mass spectrometry-based proteomics, protein biochemistry and cancer biology. He was recently awarded a prestigious Scholarship for the Next Generation of Scientists from the Cancer Research Society to support him as he establishes his research program.
Characterization of bromodomain-containing proteins in hormone-responsive cancers
Bromodomain-containing proteins are epigenetic regulators involved in many facets of the transcription process. Recently, numerous bromodomain inhibitors have been developed enabling the modulation of their activity for therapeutic benefit. Dr. Lambert’s group is currently investigating the functions of bromodomain-containing proteins in the context of hormone-responsive breast cancers to define their physical interplay with hormone receptors. In addition, Dr. Lambert is defining how specific cancer contexts impinged on bromodomain-containing proteins function and whether they generate actionable vulnerabilities that can targeted with bromodomain inhibitors.
Development of innovative functional proteomics technologies
To enable functional studies of epigenetic regulators, Dr. Lambert’s group is developing and implementing novel proteomics technologies to enable the study of proteomes, protein-protein interactions and post-translational modifications from clinically relevant samples. A particular focus of Dr. Lambert’s efforts remains the study of protein complexes associated with chromatin allowing the elucidation of the mechanisms enabling the ordered recruitment of epigenetic regulators to particular genomic loci.
2705, boulevard Laurier
R-4779
Québec, QC
Canada G1V 4G2
Latest news
- Quatorze chercheurs du CRCHU reçoivent près de 9 millions de dollars de subvention des IRSC 2020-02-28
- Équiper les scientifiques canadiens avec les meilleurs outils de recherche : 4 projets financés par le Fonds des leaders John-R.-Evans 2018-04-11
- 13 chercheurs se partagent plus de 800,000$ en subventions du CRSNG 2017-09-08
- Espinoza Romero, JeniferMaster studentCHUL+1 418-525-4444, extension 42296jenifer.espinoza-romero@crchudequebec.ulaval.ca
2705 Boulevard Laurier
R-4720
Québec, QC
Canada G1V 4G2 - Kougnassoukou Tchara, Pata-EtingDoctoral studentCHUL+1 418-525-4444, extension 42296pata-eting.kougnassoukou-tchara.1@ulaval.capata-eting.kougnassoukou-tchara@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-4720
Québec, QC
Canada G1V 4G2 - Lashgari, AnahitaEmployeeCHUL+1 418-525-4444, extension 42296anahita.lashgari.1@ulaval.caanahita.lashgari@crchudequebec.ulaval.ca
2705 Boulevard Laurier
R-4720
Québec, QC
Canada G1V 4G2 - Lauzier, Anne-MarieEmployeeCHUL+1 418-525-4444, extension 42296anne-marie.lauzier@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-4720
Québec, QC
Canada G1V 4G2 - Linteau, NaomieMaster studentCHUL+1 418-525-4444, extension 42296naomie.linteau.1@crchudequebec.ulaval.canaomie.linteau.1@ulaval.ca
2705, boulevard Laurier
R-4720
Québec, QC
Canada G1V 4G2 - Loehr, JérémyEmployeeCHUL+1 418-525-4444, extension 42296jeremy.loehr.1@ulaval.ca
2705, boulevard Laurier
R-4720
Québec, Québec
Canada G1V 4G2 - Saïdi, IsmaëlMaster studentCHUL+1 418-525-4444, extension 42296ismael.saidi@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-4720
Québec, QC
Canada G1V 4G2
Stir bar sorptive extraction based on restricted access material for the direct extraction of caffeine and metabolites in biological fluids
Journal ArticleJ Chromatogr A, 1075 (1-2), 2005.
Proteomics: from gel based to gel free
Journal ArticleAnal Chem, 77 (12), 2005.
Active projects
- Characterization of the scaffolding roles of bromodomain containing proteins at the level of chromatin, from 2017-04-01 to 2024-03-31
- Covid-19 effects on ARTErial StIffness and vascular AgiNg (CARTESIAN) study- Canada, from 2021-06-01 to 2024-05-31
- Elucidation of bromodomain functions within SWI/SNF complexes, from 2020-04-01 to 2025-03-31
- Étude des interactions bromodomain-dépendantes et de leurs impacts sur le cycle de transcription, from 2022-07-01 to 2026-06-30
- Mitochondria bound to lipid droplets as new regulators of insulin resistance, from 2022-12-01 to 2025-11-30
- Structural characterization of full-length BET proteins and their functional implications to cancer, from 2022-09-01 to 2024-08-31
- TBC1D9: therapeutic target of the aggressiveness of triple negative breast cancer, from 2023-03-01 to 2024-02-29
- Tetrahymena thermophila - un model évolutionnaire divergent pour découvrir de nouveau modes de régulation transcriptionnelle, from 2022-03-15 to 2025-03-14
Recently finished projects
- Caractérisation du protéome mitochondrial de la prostate, from 2022-09-21 to 2023-03-31
- Caractérisation fonctionnelle des régulateurs épigénétiques et de leurs rôles dans des modèles de cancer, from 2018-07-01 to 2022-06-30
- Caractérisation fonctionnelle des régulateurs épigénétiques et de leurs rôles dans des modèles de cancer, from 2018-07-01 to 2022-06-30
- COVID19 persistent symptomatology: an investigation of the metabolomic and proteomic underpinning, from 2021-06-01 to 2022-05-31
- Investigating TBC1D9 therapeutic potential for triple negative breast cancer, from 2022-09-21 to 2023-03-31
- Predict to prevent: Advanced proteomics profiling for precision medicine, from 2021-03-23 to 2022-09-30
- Using BET bromodomain inhibitors to create phenotypic lethality in melanoma, from 2020-09-01 to 2022-08-31